Fig. 7
The PRNP-dependent axis is over-represented in poor-prognosis subtypes of CRC in the IDEA-France randomized clinical trial and predicts dismal outcome. A–C Relative PRNP-CTNNB1-NR3C1 score according to the CMS classification (A), CMS combination (B) or TNM risk (C) in the IDEA France cohort. Patients with stage pT1-T3 and pN1 were classified as low TNM risk and those with pT4 and / or pN2 as high TNM risk. D–F Scatter plots showing the correlation between the PRNP-CTNNB1-NR3C1 score and the mesenchymal (D) or the fibroblast (E) scores in the IDEA France cohort. F Density plot showing the distribution of correlation coefficients with the PRNP-CTNNB1-NR3C1 score in the IDEA France cohort highlighting the top-ranked correlation with the mesenchymal score. G Sankey plots showing the correspondence between low or high PRNP-CTNNB1-NR3C1 score and CMS subclasses. H, I Kaplan–Meier curves comparing time to recurrence in patients with low or high PRNP-CTNNB1-NR3C1 score in the entire IDEA France cohort (H) or in the subset of patients having received chemotherapy during 3 months (I)